15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 10 firms covering Taysha Gene Therapies Inc, 10 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $10.00 to $17.00, a moderate spread. The average target of $12.80 sits 135% above the current $5.46. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 9 to 10 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.12 next quarter toward $-0.43 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 ratings
Moderate Buy
Strong Buy110%
Buy990%
Hold00%
Sell00%
Strong Sell00%
Based on 10 analysts giving stock ratings to Taysha Gene Therapies Inc.
As of Jul, 10 of 10 firms rate TSHA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
TSHA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.12
Range $-0.15 – $-0.09 · 5 analysts · +37% YoY
Next period, 5 analysts expect Taysha Gene Therapies Inc to earn $-0.12 a share (range $-0.15 – $-0.09), versus $-0.09 a year earlier. Full-year consensus is $-0.44, growing to $-0.43 the year after.
REVENUE · NEXT QUARTER
$566.7K
Range $0 – $3.8M · 5 analysts
Revenue is expected to reach $566.7K (range $0 – $3.8M). Full-year consensus is $1.8M, rising to $29.7M next year.
Top analysts covering Taysha Gene Therapies Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TSHA.
#1
Silvan Tuerkcan
JMP Securities · Rank #29
Buy
$11.00+101.6% to target
Overall win rate
50%
+ Follow
#2
Geulah Livshits
Chardan Capital · Rank #100
Buy
$12.00+120.0% to target
Overall win rate
44%
+ Follow
#3
Kristen Kluska
Cantor Fitzgerald · Rank #162
Buy
$19.00+248.3% to target
Overall win rate
38%
+ Follow
#4
TA
Tazeen Ahmad
B of A Securities · Rank #275
Buy
$10.00+83.3% to target
Overall win rate
41%
+ Follow
#5
Gil Blum
Needham · Rank #298
Buy
$12.00+120.0% to target
Overall win rate
24%
+ Follow
TSHA stock forecast FAQ
What is TSHA's average 12-month price target?+
The 10 analysts with a live target average $12.80 for Taysha Gene Therapies Inc over the next 12 months, ranging from a $17.00 high to a $10.00 low.
Is TSHA stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 10 analyst ratings, 10 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for TSHA?+
The Street-high target is $17.00 (Canaccord Genuity), and the Street-low is $10.00 (B of A Securities). The average of all 10 active targets is $12.80.
How many Wall Street analysts cover TSHA?+
10 analysts have an active rating on Taysha Gene Therapies Inc, and 10 firms carry a live 12-month price target.
Who is the most accurate analyst covering TSHA?+
Among analysts who currently cover TSHA, Silvan Tuerkcan of JMP Securities has the strongest overall Quantellect track record (Rank #29). Their current call is Buy with a $11.00 target.
What is Taysha Gene Therapies Inc's projected EPS for next quarter?+
The consensus estimate is $-0.12 per share (range $-0.15 – $-0.09) across 5 analysts. Full-year EPS is projected at $-0.44, rising to $-0.43 the following year.
How much revenue is Taysha Gene Therapies Inc expected to report next quarter?+
Consensus revenue is $566.7K (range $0 – $3.8M). Full-year revenue is projected at $1.8M, growing to $29.7M next year.
Have analysts been upgrading or downgrading TSHA lately?+
As of Jul, 10 of 10 firms rate TSHA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TSHA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
